YSCH-01

AXP000044.1 · Oncolytic virus

Platform
adenovirus (Ad5, E1B-55kDa deleted; CTGVT/ZD55 design)
Originator
Shanghai Yuansong Biotechnology
Sponsor
Shanghai Yuansong Biotechnology

Names

NameTypeSource
YSCH-01preferred name, codecurator, ncit
Recombinant L-IFN adenovirus injectionsynonymctgov

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (ZD55/CTGVT)
Replication
conditionally replicating
Modifications
E1B-55kDa deleted
Transgenes
interferon (L-IFN)
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C186376

Approvals

No regulatory approval recorded.

Clinical trials (5)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07307053Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruitingPhase 1/22026-01-012029-01-31600Advanced Solid Tumors; Metastatic Solid Tumors; Rare Malignant Neoplasm
NCT07793500YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)RecruitingEarly phase 12025-11-272026-10-0936Advanced Solid Tumor; NSCLC
NCT07538128Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent GlioblastomaRecruitingEarly phase 12025-01-092026-11-2710Recurrent Glioblastoma
NCT05914935Safety and Tolerability Study of Recombinant L-IFN Adenovirus Injection in Patients With Recurrent GlioblastomaUnknownEarly phase 12023-06-272024-06-126Recurring Glioblastoma
NCT05180851Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical StudyUnknownEarly phase 12021-11-302023-05-3028Bladder Cancer; Breast Cancer; Cervical Carcinoma; Head and Neck Cancer; Lung Cancer; Melanoma; Ovarian Carcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 38719544Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial.Journal for immunotherapy of cancer2024cited by trial NCT05180851

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41339296Interleukin-8-induced tumor self-rampart spatially confines oncolytic virotherapy in glioblastoma.Neuro-oncology2026name in abstract: YSCH-01
PMID 40342022Preclinical Toxicity Study and Tissue Distribution of YSCH- 01 Injection via Intratumoral Injection, Intravenous Injection, and Intraperitoneal Injection in Syrian Hamsters.Pharmaceutical research2025name in title: YSCH-01
PMID 41372267Therapeutic efficacy of oncolytic adenovirus YSCH-01 in osteosarcoma evaluated in PDX and CDX mouse models.Scientific reports2025name in title: YSCH-01
PMID 37789452Potent antitumor efficacy of human dental pulp stem cells armed with YSCH-01 oncolytic adenovirus.Journal of translational medicine2023name in title: YSCH-01
PMID 37841695Double-modified oncolytic adenovirus armed with a recombinant interferon-like gene enhanced abscopal effects against malignant glioma.Neuro-oncology advances2023name in abstract: YSCH-01

Notes

Recombinant oncolytic adenovirus expressing an interferon ('L-IFN'), described by its developers as cancer-targeting gene-virotherapy (CTGVT). Trials NCT05180851, NCT05914935. Originator company name taken from the product code, not from a primary source.

How to cite

YSCH-01 (AXP000044.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000044.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.